lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Drug Testing and Analysis

• Publication date

  2017-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/dta.2202PMID 28378453
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Furan- and Thiophene-2-Carbonyl Amino Acid Derivatives Activate Hypoxia-Inducible Factor via Inhibition of Factor Inhibiting Hypoxia-Inducible Factor-1

  2018cited by this paper
• Investigation of the metabolites of the HIF stabilizer FG‐4592 (roxadustat) in five different in vitro models and in a human doping control sample using high resolution mass spectrometry

  2017cited by this paper
• Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls.

  2017cited by this paper
• New insights for identification of doping with recombinant human erythropoietin micro-doses after high hydration.

  2016cited by this paper
• A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.

  2016cited by this paper
• Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: Investigation on a positive case.

  2016cited by this paper
• Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.

  2016cited by this paper
• Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls.

  2016cited by this paper
• HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond

  2016cited by this paper
• The ESA scenario gets complex: from biosimilar epoetins to activin traps.

  2015cited by this paper
• A synthetic stimulant never tested in humans, 1,3-dimethylbutylamine (DMBA), is identified in multiple dietary supplements.

  2015cited by this paper
• Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

  2015cited by this paper
• Prevalence of Doping Use in Elite Sports: A Review of Numbers and Methods

  2014cited by this paper
• Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies

  2014cited by this paper
• Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects

  2014cited by this paper
• The effects of two weeks of recombinant growth hormone administration on the response of IGF-I and N-terminal pro-peptide of collagen type III (P-III-NP) during a single bout of high resistance exercise in resistance trained young men.

  2013cited by this paper
• DMAA as a dietary supplement ingredient.

  2012cited by this paper
• Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis.

  2012cited by this paper
• Strategies for extended serum half-life of protein therapeutics.

  2011cited by this paper
• The list of prohibited substances and methods in sport: structure and review process by the world anti-doping agency.

  2011cited by this paper
• Growth hormone doping: a review

  2011cited by this paper
• Development of liquid chromatography-tandem mass spectrometry-based analytical assays for the determination of HIF stabilizers in preventive doping research.

  2011cited by this paper
• High-throughput screening for various classes of doping agents using a new 'dilute-and-shoot' liquid chromatography-tandem mass spectrometry multi-target approach.

  2011cited by this paper
• Effect of single doses of methoxypolyethylene glycol-epoetin beta (CERA, Mircera™) and epoetin delta (Dynepo™) on isoelectric erythropoietin profiles and haematological parameters.

  2011cited by this paper
• Effects of recombinant human erythropoietin in normal humans

  2011cited by this paper
• Chronic kidney disease-associated anemia: new remedies.

  2010cited by this paper
• Detection of continuous erythropoietin receptor activator in blood and urine in anti-doping control

  2009cited by this paper
• Unusual mass spectrometric dissociation pathway of protonated isoquinoline-3-carboxamides due to multiple reversible water adduct formation in the gas phase

  2009cited by this paper
• SARCOSYL-PAGE: a new method for the detection of MIRCERA- and EPO-doping in blood.

  2009cited by this paper
• "Because I know it will!": placebo effects of an ergogenic aid on athletic performance.

  2007cited by this paper
• Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.

  2006cited by this paper
• Chemical transformation of protoberberines. XII A novel synthesis of rhoeadine alkaloids. An alternative synthesis of a key intermediate, benzindenoazepine, for a synthesis of (.+-.)-cis-alpinigenine and (.+-.)-cis-alpinine from palmatine.

  1987cited by this paper
• A FIRST AND STEREOSELECTIVE SYNTHESIS OF (±)-RADDEANAMINE

  1985cited by this paper
• Chemical Transformation of Protoberberines. VIII. A Novel Synthesis of (±)-Fumaricine and a Formal Synthesis of (±)-Alpinigenine

  1985cited by this paper
• A highly stereoselective synthesis of (±)-dihydrofumariline-1

  1985cited by this paper
• Chemical transformation of protoberberines. VII. Efficient conversion of protoberberines into benzindenoazepines via 8,14-cycloberbines.

  1985cited by this paper

• Roxadustat as a Hypoxia-Mimetic Agent: Erythropoietic Mechanisms, Bioanalytical Detection, and Regulatory Considerations in Sports Medicine

  2025cites this paper
• American College of Sports Medicine Expert Consensus Statement: Blood Doping in Sport.

  2025cites this paper
• Detection of FG-4592 and metabolites in equine plasma, urine and hair following oral administration.

  2024cites this paper
• Long-Term Excretion of Roxadustat in Urine.

  2024cites this paper
• Comparison between standard hematological parameters and blood doping biomarkers in dried blood spots within the athlete population of Swiss Sport Integrity

  2024cites this paper
• Roles of Hypoxia-Inducible Factor-Prolyl Hydroxylases in Aging and Disease.

  2024cites this paper
• In-Silico aided screening and characterization results in stability enhanced Novel Roxadustat co-crystal.

  2023cites this paper
• Untargeted Detection of HIF Stabilizers in Doping Samples: Activity-Based Screening with a Stable In Vitro Bioassay.

  2023cites this paper
• First detection/quantification of roxadustat in hair with a new liquid chromatography with tandem mass spectrometry method: application to a treated patient.

  2023cites this paper
• Blood doping — physiological background, substances and techniques used, current and future detection methods

  2023cites this paper
• In silico and in vitro human metabolism of IOX2, a performance-enhancing doping agent.

  2023cites this paper
• A critical review of Roxadustat formulations, solid state studies, and analytical methodology

  2023influential citation
• Pharmacokinetic Study of Vadadustat and High-Resolution Mass Spectrometric Characterization of its Novel Metabolites in Equines for the Purpose of Doping Control.

  2022cites this paper
• Metabolic study of hypoxia-inducible factor stabilizers BAY 87-2243, MK-8617, and PT-2385 in equine liver microsomes for doping control.

  2022cites this paper
• Comprehensive metabolic study of IOX4 in equine urine and plasma using liquid chromatography/electrospray ionization Q Exactive high-resolution mass spectrometer for the purpose of doping control.

  2021cites this paper
• Identification of HIF stabilizer Roxadustat and its possible metabolites in thoroughbred horses for doping control.

  2021cites this paper
• Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease.

  2021cites this paper
• Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial.

  2021cites this paper
• Olympic anti-doping laboratory: the analytical technological road from 2016 Rio De Janeiro to 2021 Tokyo.

  2021cites this paper
• A Scalable Synthesis of Roxadustat (FG-4592)

  2021cites this paper
• UPLC-MS-Based Procedures to Detect Prolyl-hydroxylase Inhibitors of HIF in Urine.

  2020cites this paper
• Implementation of the HIF activator IOX-2 in routine doping controls - pilot study data.

  2020cites this paper
• Automated sample preparation for the detection and confirmation of hypoxia-inducible factor stabilizers in urine.

  2020cites this paper
• Analytical Approaches in Human Sports Drug Testing - Recent Advances, Challenges, and Solutions.

  2020cites this paper
• Annual banned-substance review: Analytical approaches in human sports drug testing.

  2019cites this paper
• Erythropoietin: novelties in antidoping research

  2019cites this paper
• ExActa HIF prolyl hydroxylase inhibitors—The new lifestyle drug?

  2019cites this paper
• Analytical challenges in sports drug testing

  2018cites this paper
• Multiwavelength UV-metric and pH-metric determination of the dissociation constants of the hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat

  2018cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 251 Structural Determination of Drug Metabolites from Doping Classed Compounds Using Mass Spectrometry

  2018influential citation
• Furan- and Thiophene-2-Carbonyl Amino Acid Derivatives Activate Hypoxia-Inducible Factor via Inhibition of Factor Inhibiting Hypoxia-Inducible Factor-1

  2018cites this paper
• Identification and characterization of novel long-term metabolites of oxymesterone and mesterolone in human urine by application of selected reaction monitoring GC-CI-MS/MS.

  2017cites this paper
• The 35th Manfred Donike workshop on doping analysis.

  2017cites this paper